Intravitreal Bevacizumab for the Treatment of Central Serous Chorioretinopathy
|
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
| ClinicalTrials.gov Identifier: NCT00418431 |
|
Recruitment Status
: Unknown
Verified June 2006 by Asociación para Evitar la Ceguera en México.
Recruitment status was: Recruiting
First Posted
: January 4, 2007
Last Update Posted
: January 4, 2007
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Central serous chorioretinopathy (CSC) has been known since it was first described by Von Graefe and termed “idiopathic detachment of the macula” in 1866, is a well-characterized disorder leading to serous neurosensory elevation of the central macula. The acute form of the disease is associated with focal leakage at the level of the retinal pigment epithelium (RPE) demonstrated with fluorescein angiography (FA). The disorder is self-limited in the majority of patients, who also regain excellent vision. Occasionally, the neurosensory detachment persists and leads to pigment epithelial and photoreceptor damage with visual impairment.
The purpose of this clinical study is report the use of intravitreal bevacizumab is a new option in the treatment of the chronic or recurrent CSC.
| Condition or disease | Intervention/treatment | Phase |
|---|---|---|
| Central Serous Chorioretinopathy | Drug: Intravitreal injection of Bevacizumab | Phase 2 Phase 3 |
| Study Type : | Interventional (Clinical Trial) |
| Allocation: | Non-Randomized |
| Intervention Model: | Single Group Assignment |
| Masking: | None (Open Label) |
| Primary Purpose: | Treatment |
| Study Start Date : | April 2006 |
| Study Completion Date : | August 2006 |
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
| Ages Eligible for Study: | 20 Years to 50 Years (Adult) |
| Sexes Eligible for Study: | All |
Inclusion Criteria
- Any visual acuity.
- Central serous chorioretinopathy
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00418431
| Contact: Mitzy E Torres Soriano, MD | 525510841400 ext 1172 | retinamex@yahoo.com | |
| Contact: Hugo Quiroz-Mercado, MD | 525510841400 ext 1171 | hugoquiroz@yahoo.com |
| Mexico | |
| Asociacion para Evitar la Ceguera en Mexico | Recruiting |
| Mexico DF, DF, Mexico, 04030 | |
| Contact: Mitzy E Torres Soriano, MD 5255510841400 ext 1171 mitzytorres@yahoo.com | |
| Sub-Investigator: Maura Abraham, MD | |
| Sub-Investigator: Orlando Ustariz, MD | |
| Sub-Investigator: Gerardo Garcia Aguirre | |
| Sub-Investigator: Veronica Kon-Jara, MD | |
| Sub-Investigator: Hugo Quiroz-Mercado, MD | |
| Sub-Investigator: Jose L Guerrero, MD | |
| Principal Investigator: | Mitzy E Torres Soriano, MD | APEC |
| ClinicalTrials.gov Identifier: | NCT00418431 History of Changes |
| Other Study ID Numbers: |
APEC-0016 |
| First Posted: | January 4, 2007 Key Record Dates |
| Last Update Posted: | January 4, 2007 |
| Last Verified: | June 2006 |
Additional relevant MeSH terms:
|
Central Serous Chorioretinopathy Retinal Diseases Eye Diseases Bevacizumab Angiogenesis Inhibitors |
Angiogenesis Modulating Agents Growth Substances Physiological Effects of Drugs Growth Inhibitors Antineoplastic Agents |